Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 28;9(10):1345.
doi: 10.3390/biomedicines9101345.

HCC and Molecular Targeting Therapies: Back to the Future

Luca Rinaldi  1 , Erica Vetrano  1 , Barbara Rinaldi  2 , Raffaele Galiero  1 , Alfredo Caturano  1 , Teresa Salvatore  3 , Ferdinando Carlo Sasso  1
Affiliations
Review

HCC and Molecular Targeting Therapies: Back to the Future

Luca Rinaldi et al. Biomedicines. .

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of death from cancer in the world. Recently, the effectiveness of new antiviral therapies and the HBV vaccine have reduced HCC's incidence, while non-alcoholic steato-hepatitis is an emerging risk factor. This review focuses on antiangiogenic molecules and immune checkpoint inhibitors approved for HCC treatment and possible future approaches. Sorafenib was the first drug approved for the treatment of advanced HCC (aHCC) and it has been shown to increase survival by a few months. Lenvatinib, a multikinase inhibitor, has shown non-inferiority in survival compared with sorafenib and an improvement in progression-free survival (PFS). The combination of atezolizumab (an anti-PDL1 antibody) and bevacizumab (an anti-VEGF antibody) was the first drug combination approved for HCC, demonstrating improved survival compared with sorafenib (19.2 vs. 13.4 months). As a second line of therapy, three regimens (regorafenib, cabozantinib, and ramucirumab) have been approved for the treatment of aHCC after progression on sorafenib according to guidelines. Furthermore, nivolumab, pembrolizumab, and nivolumab plus ipilimumab have been approved by the FDA (2017, 2018, and 2020, respectively). Finally, immune target therapy, cancer vaccines, and epigenetic drugs represent three new possible weapons for the treatment of HCC.

Keywords: HCC; drugs; liver; trials.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
FDA-approved and main drugs from ongoing trials for HCC.
See this image and copyright information in PMC

References

    1. McGlynn K.A., Petrick J.L., El-Serag H.B. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73((Suppl. S1)):4–13. doi: 10.1002/hep.31288. - DOI - PMC - PubMed
    1. Ascione A., Fontanella L., Imparato M., Rinaldi L., De Luca M. Mortality from cirrhosis and hepatocellular carcinoma in Western Europe over the last 40 years. Liver Int. 2017;37:1193–1201. doi: 10.1111/liv.13371. - DOI - PubMed
    1. Lenti M.V., Pasina L., Cococcia S., Cortesi L., Miceli E., Caccia Dominioni C., Pisati M., Mengoli C., Perticone F., Nobili A., et al. Mortality rate and risk factors for gastrointestinal bleeding in elderly patients. Eur. J. Intern. Med. 2019;61:54–61. doi: 10.1016/j.ejim.2018.11.003. - DOI - PubMed
    1. Rinaldi L., Perrella A., Guarino M., De Luca M., Piai G., Coppola N., Pafundi P.C., Ciardiello F., Fasano M., Martinelli E., et al. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: A prospective multicentre study. J. Transl. Med. 2019;17:292. doi: 10.1186/s12967-019-2033-x. - DOI - PMC - PubMed
    1. Sagnelli E., Macera M., Russo A., Coppola N., Sagnelli C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48:7–17. doi: 10.1007/s15010-019-01345-y. - DOI - PubMed